168 related articles for article (PubMed ID: 16421713)
1. Mangafodipir trisodium-enhanced MR imaging of pancreatic disease.
Boraschi P; Donati F; Gigoni R; Caramella D; Boggi U; Falaschi F; Bartolozzi C
Eur Radiol; 2006 May; 16(5):988-97. PubMed ID: 16421713
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance with manganese-DPDP (mangafodipir) of focal solid pancreatic lesions.
Zanello A; Nicoletti R; Brambilla P; Boccuni R; Di Carlo V; Staudacher C; Del Maschio A
Radiol Med; 2004 Sep; 108(3):194-207. PubMed ID: 15343134
[TBL] [Abstract][Full Text] [Related]
3. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
4. MRI with mangafodipir trisodium in the detection of pancreatic tumours: comparison with helical CT.
Rieber A; Tomczak R; Nüssle K; Klaus H; Brambs HJ
Br J Radiol; 2000 Nov; 73(875):1165-9. PubMed ID: 11144793
[TBL] [Abstract][Full Text] [Related]
5. Defining intrahepatic biliary anatomy in living liver transplant donor candidates at mangafodipir trisodium-enhanced MR cholangiography versus conventional T2-weighted MR cholangiography.
Lee VS; Krinsky GA; Nazzaro CA; Chang JS; Babb JS; Lin JC; Morgan GR; Teperman LW
Radiology; 2004 Dec; 233(3):659-66. PubMed ID: 15516606
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.
Schima W; Függer R; Schober E; Oettl C; Wamser P; Grabenwöger F; Ryan JM; Novacek G
AJR Am J Roentgenol; 2002 Sep; 179(3):717-24. PubMed ID: 12185052
[TBL] [Abstract][Full Text] [Related]
7. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
8. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
Youk JH; Lee JM; Kim CS
AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
[TBL] [Abstract][Full Text] [Related]
9. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.
Scharitzer M; Schima W; Schober E; Reimer P; Helmberger TK; Holzknecht N; Stadler A; Ba-Ssalamah A; Weber M; Wrba F
J Comput Assist Tomogr; 2005; 29(2):181-90. PubMed ID: 15772534
[TBL] [Abstract][Full Text] [Related]
10. Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging.
Coffin CM; Diche T; Mahfouz A; Alexandre M; Caseiro-Alves F; Rahmouni A; Vasile N; Mathieu D
Eur Radiol; 1999; 9(3):444-9. PubMed ID: 10087113
[TBL] [Abstract][Full Text] [Related]
11. [MR imaging of pancreatic lesions with Mn-DPDP. A histopathologic correlation].
Dobritz M; Fellner FA; Baum U; Nömayr A; Lell M; Klein P; Papadopoulos T; Bautz W
Rofo; 2002 Jul; 174(7):893-7. PubMed ID: 12101481
[TBL] [Abstract][Full Text] [Related]
12. [Mangafodipir trisodium-enhanced magnetic resonance cholangiography for detection of bile leaks].
Assaban M; Aubé C; Lebigot J; Ridereau-Zins C; Hamy A; Caron C
J Radiol; 2006 Jan; 87(1):41-7. PubMed ID: 16415779
[TBL] [Abstract][Full Text] [Related]
13. Secretin-stimulated multi-detector CT versus mangafodipir trisodium-enhanced MR imaging plus MRCP in characterization of non-metastatic solid pancreatic lesions.
Boraschi P; Donati F; Gigoni R; Salemi S; Faggioni L; Del Chiaro M; Boggi U; Bartolozzi C; Falaschi F
Dig Liver Dis; 2009 Nov; 41(11):829-37. PubMed ID: 19303825
[TBL] [Abstract][Full Text] [Related]
14. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
Rofsky NM; Earls JP
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
[TBL] [Abstract][Full Text] [Related]
15. MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer.
Romijn MG; Stoker J; van Eijck CH; van Muiswinkel JM; Torres CG; Laméris JS
J Magn Reson Imaging; 2000 Aug; 12(2):261-8. PubMed ID: 10931589
[TBL] [Abstract][Full Text] [Related]
16. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT.
Oudkerk M; Torres CG; Song B; König M; Grimm J; Fernandez-Cuadrado J; Op de Beeck B; Marquardt M; van Dijk P; de Groot JC
Radiology; 2002 May; 223(2):517-24. PubMed ID: 11997562
[TBL] [Abstract][Full Text] [Related]
17. Using contrast-enhanced MR cholangiography with IV mangafodipir trisodium (Teslascan) to evaluate bile duct leaks after cholecystectomy: a prospective study of 11 patients.
Vitellas KM; El-Dieb A; Vaswani KK; Bennett WF; Fromkes J; Ellison C; Bova JG
AJR Am J Roentgenol; 2002 Aug; 179(2):409-16. PubMed ID: 12130442
[TBL] [Abstract][Full Text] [Related]
18. MR imaging of pancreatic lesions. Comparison of manganese-DPDP and gadolinium chelate.
Diehl SJ; Lehmann KJ; Gaa J; McGill S; Hoffmann V; Georgi M
Invest Radiol; 1999 Sep; 34(9):589-95. PubMed ID: 10485075
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium.
Mayo-Smith WW; Schima W; Saini S; Slater GJ; McFarland EG
AJR Am J Roentgenol; 1998 Mar; 170(3):649-52. PubMed ID: 9490946
[TBL] [Abstract][Full Text] [Related]
20. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
